Prismmulti-framework research
Prism

See every stock through 15+ investor lenses. Research, decide, document — without leaving the page.

For research and education only — not investment advice.

Research
  • Browse
  • Screener
  • Markets
  • Superinvestors
  • Insider tracker
Tools
  • Backtest
  • Calculators
  • Compare
  • Copilot
Workspace
  • Portfolio
  • Watchlist
  • Alerts
  • Weekly digest
  • Learn
© 2026 Prism Finance. All data illustrative.GlossaryContact
  • Browse
  • Screener
  • Disagree
  • Portfolio
ABT logo

ABT

Abbott Laboratories
HealthcareMedical DevicesIncome
$83.82 · 15min delay
β 0.65

A high-quality large-cap income stock trading near fair value. Frameworks sharply disagree on it.

Download report

52-wk low $81.9752-wk high $139.06

Mkt Cap

$146.00B

P/E

—

PEG

1.25

P/B

2.80

Dividend

3.05%

ROE

12.3%

About the business

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Who would buy ABT?

Consensus 14/100 · Mixed · Investors are split.

2 2 11

Endorses

· 2 frameworks
  • Dividend Growth School· Dividend Income88/100

    Dividend Yield > 2% 3.0% clears "> 2.0%".

  • Cyclical Value School· Deep Cyclical88/100

    Down > 30% from 52-wk high -39.7% clears "< -30.0%".

Rejects

· 3 frameworks
Insider activity · Positive

3 insiders bought shares in the open market

Strength 95/100

Over the last ~6 months 3 different insiders made open-market purchases totalling $4.2M, against $688K of selling (including planned 10b5-1 disposals). Multi-insider open-market buying is one of the more durable positive signals because it reflects fresh-dollar conviction rather than vesting or diversification. Over the 6M window, insiders are net buyers by 316,747 shares.

In Prism's context

Insider buying adds modest supporting evidence alongside the framework read (Fails criteria).

InsiderRoleTypeDateSharesAvg priceValueOwn
STARKS DANIEL JDirectorOpen-market buyApr 27, 202610,000$92.65$927KDirect
GONZALEZ PATRICIA PAOLADirectorAward / grantApr 24, 20262,286$0.00$0Direct
AHUJA NITA M.D.DirectorAward / grantApr 24, 20262,286$0.00$0Direct
BABINEAUX CLAIRE FONTENOTDirectorAward / grantApr 24, 20262,286$0.00$0Direct
MCDEW DARREN WDirectorAward / grantApr 24, 20262,286$0.00$0Direct
STARKS DANIEL JDirectorAward / grantApr 24, 20262,286$0.00$0Direct
ROMAN MICHAEL FDirectorAward / grantApr 24, 20262,286$0.00$0Direct
KUMBIER MICHELLE ADirectorAward / grantApr 24, 20262,286$0.00$0Direct
STRATTON JOHN G.DirectorAward / grantApr 24, 20262,286$0.00$0Direct
MCKINSTRY NANCYDirectorAward / grantApr 24, 20262,286$0.00$0Direct
O GRADY MICHAEL GDirectorAward / grantApr 24, 20262,286$0.00$0Direct
BLOUNT SALLY EDirectorAward / grantApr 24, 20262,286$0.00$0Direct
CONROY KEVIN TDirectorAward / grantApr 24, 20262,286$0.00$0Direct
BOUDREAU PHILIP PChief Financial OfficerOpen-market buyApr 23, 20262,200$91.50$201KIndirect
ORVILLE JACOB AOfficerAward / grantMar 23, 202613,255$0.00$0Direct
MORRONE LOUIS HOfficerOpen-market sellMar 2, 20261,144$115.58$132KDirect
SHROFF ERICOfficerOpen-market sellMar 2, 2026709$115.58$82KDirect
CUSHMAN ELIZABETH CGeneral CounselOpen-market sellMar 2, 2026263$115.58$30KDirect
MCCOY JOHN A. JROfficerOpen-market sellMar 2, 2026585$115.58$68KDirect
MORELAND MARY KOfficerOpen-market sellMar 2, 2026613$115.58$71KDirect
SALVADORI DANIEL GESUA SIVEOfficerOpen-market sellMar 2, 2026885$115.58$102KDirect
BOUDREAU PHILIP PChief Financial OfficerAward / grantFeb 24, 202627,997$0.00$0Direct
MORRONE LOUIS HOfficerAward / grantFeb 24, 202615,418$0.00$0Direct
SHROFF ERICOfficerAward / grantFeb 24, 202610,873$0.00$0Direct
CUSHMAN ELIZABETH CGeneral CounselAward / grantFeb 24, 202615,031$0.00$0Direct
MCCOY JOHN A. JROfficerAward / grantFeb 24, 20265,373$0.00$0Direct
SCOGGINS CHRISTOPHER JOfficerAward / grantFeb 24, 202618,502$0.00$0Direct
MORELAND MARY KOfficerAward / grantFeb 24, 202613,951$0.00$0Direct
FORD ROBERT B.Chief Executive OfficerAward / grantFeb 24, 202683,464$0.00$0Direct
SALVADORI DANIEL GESUA SIVEOfficerAward / grantFeb 24, 202621,644$0.00$0Direct
EARNHARDT LISA DOfficerAward / grantFeb 24, 202627,056$0.00$0Direct
STARKS DANIEL JDirectorOpen-market buyFeb 4, 202610,000$108.73$1.09MDirect
FORD ROBERT B.Chief Executive OfficerOpen-market buyJan 23, 202618,800$107.13$2.01MIndirect
SALVADORI DANIEL GESUA SIVEOfficerStock Gift at price 123.28 per share.Dec 11, 20251,536$123.28$189KDirect
SHROFF ERICOfficerOpen-market sellNov 25, 20251,586$128.02$203KDirect

Insider activity from Yahoo Finance (quoteSummary: insiderTransactions + netSharePurchaseActivity). Cached 6 hours. · Insiders hold 0.5% of shares outstanding.

Net 6M: +316,747 sh

Price history

—
Loading…

Drag across the chart to select a custom period — all analysis below refocuses to that window.

What this means: Price near 52-week lows confirms what most frameworks are already flagging: the market is discounting deteriorating fundamentals.

Premium view

AI summaries

Members get a plain-English 'what matters now' brief plus an explanation of why the price is moving, grounded in Prism's framework scores.

Premium view

Full framework decision report

See how Lynch, Buffett, Graham, Greenblatt, Fisher and more each score this stock — with every rule, threshold, and reason exposed.

Premium view

Peer comparison + AI read-through

See how this stock stacks up against its closest peers on valuation, growth, and returns — with a written peer summary.

What would ABT do to your portfolio?

Add Abbott Laboratories at a hypothetical weight and Prism recalculates your whole book:

Risk metrics

Sharpe, Sortino, volatility, max drawdown, beta — before and after.

Sector concentration

How much this shifts your top sector weight and overall diversification.

Archetype tilt

Whether this leans your book more toward Quality, Value, Growth, Deep Value, Income, or Momentum.

ABT is currently tagged:IncomeFails criteria (14/100)

Portfolio analytics are part of the member experience.

Sign in to run this simulation
Probabilistic recommendation· rec-v1.0.0-2026-04

Abbott Laboratories · ABT

ABT: 48% estimated probability of outperforming over the next 12M window. 1 of 6 signal families negative (medium confidence). Strongest support: 3 insiders buying. Main risk to monitor: 91% above fair value.

Outperform prob.
48%
vs S&P 500 · 12M
medium confidence
Expected return
-6.2% → +17.8%
mid +5.8% / yr
Downside (p20)
-9.8%
stress -19.5%
Data quality
95/100
Excellent

Probabilistic research output, not financial advice. Prism recommendations are based on available data, historical relationships, and model assumptions. They do not guarantee future returns. Conduct independent due diligence before any investment decision.

Backtested and similar-setup statistics may be affected by survivorship bias, look-ahead bias, overfitting, transaction costs, liquidity constraints, and data limitations. Probability estimates are anchored heuristics — not validated forecasts — until the walk-forward backtest pipeline is in place.

Prism Score

Composite 51/100. Strongest contribution from quality; weakest from valuation. Risk patterns shaved 2 points off the composite.

Composite
51
/ 100
Mixed
Deep valueval.
71/ 100

P/B 2.80× · FCF yield 4.3%

Margin of safetyval.
0/ 100

91% above fair value

Bull · base · bear scenarios

Three plausible paths over a 5-year horizon.

Indicative only. Probabilities are model-implied weights for stress-testing — not forecasts.

Bull
~20%
$57.16
-7.4% / yr (5y)

A turnaround takes hold: margin recovers toward peer averages, revenue stabilises, and the market re-prices the asset value rather than the running earnings.

Drivers
  • • Margin expands by 200–400 bps from 13%
  • • Stranded asset value crystallises
  • • Multiple re-rates one full turn higher
Base
~45%
$43.97
-12.1% / yr (5y)

No deterioration, no surprise re-acceleration. 13% operating margin and 8% top-line growth chug along; the multiple slowly converges to the central fair-value estimate.

Global value comparison

Abbott Laboratories vs sector medians — GCC, MENA, and Global ex-US.

Sector: Healthcare. MENA-aware investors can sanity-check whether the US name is offering value relative to regional peers.

MetricABTGCC medianMENA medianGlobal ex-US
P/E (TTM)—24.0×—20.0×
P/B2.80×4.80×—3.80×
Dividend yield3.05%1.40%—1.80%
ROE12.3%
Earnings reaction explainer

ABT missed by -9.9%.

Miss· -9.9%

Reported EPS $1.15 vs $1.28 expected — a manageable miss. Whether it matters depends on cause: input-cost pressure or one-off charges shrug off; demand softness compounds. Trailing operating margin: 13.5%.

  • Quality investorsNegative

    A miss without a clear one-off cause raises questions about the durability of the margin structure.

  • Growth investorsNegative

    Decelerating growth + a miss is the pattern that resets multiples — even a small miss matters when the prior multiple was full.

  • Value investorsNeutral

    Already cheap; the question is whether the deterioration is cyclical (digestible) or structural (avoid).

News & events

Next earnings

Thu, Jul 16 · consensus EPS $1.28 · last actual $1.15

  • 1 Stat That Shows How Tech Absolutely Dominates the Stock Market

    Barrons.com · just now

  • A Look At Abbott Laboratories (ABT) Valuation After Mixed Q1 Results And Baby Formula Legal Ruling

    Simply Wall St. · just now

  • What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk

    Motley Fool · just now

Key Metrics at a Glance

P/E Ratio (TTM)

N/A

PEG Ratio

1.25

P/B Ratio

2.80

EPS Growth

-19.7%

Revenue Growth

7.8%

Debt / Equity

0.65

Net Cash / Share

$-15.41

Return on Equity

12.3%

Gross Margin

56.5%

Operating Margin

13.5%

FCF / Share

$3.64

Current Ratio

1.39

Peter Lynch
· Lynch GARP
0/100

PEG < 1 (growth at a discount) is 1.25× — fails "< 1.00×".

  • Joel Greenblatt· Magic Formula0/100

    ROE > 20% is 12.3% — fails "> 20.0%".

  • Philip Fisher· Fisher Growth0/100

    Revenue Growth > 15% is 7.8% — fails "> 15.0%".

  • See the full rule-by-rule drill-down below
    Prism Score
    51/100
    Low agreement
    Signal families · 1 of 6 signal families negative
    Agreement: Low
    • Valuationnegative

      Trades meaningfully above the fair-value range — limited margin of safety.

      91% above fair valueReverse DCF: aggressive expectations
      17
      /100
    • Qualityneutral

      Quality is mixed — some strengths, some softness.

      ROE 12%Gross 57%EPS shrinking -20%
      52
      /100
    • Balance sheetneutral

      Capital structure is unremarkable — neither a stress nor a tailwind.

      50
      /100
    • Momentumnegative

      Price has been weak — momentum is a headwind.

      Near 52w lows (3%)
      40
      /100
    • Behaviouralpositive

      Insiders and / or superinvestors are accumulating — informed-money tailwind.

      3 insiders buying
      68
      /100
    • Catalysts & eventsneutral

      Mixed catalyst picture.

      EPS miss (-10%)3.0% covered yield1 medium-severity flag
      43
      /100
    Positive drivers
    • • 3 insiders buying
    Key risks
    • • 91% above fair value
    • • Reverse DCF: aggressive expectations
    • • Near 52w lows (3%)
    • • Operating leverage appears to have reversed
    Suggested diligence questions
    • 1. Is insider buying coming from operators with informed perspective on near-term results?
    • 2. Operating-margin trend
    Similar historical setups[MOCK DATA]

    Among 97 historical setups with similar Prism Score and signal-agreement profiles, 49% beat the benchmark over the next 12 months, with average excess return of -0.2% / yr.

    Probabilistic research output — not financial advice.
    View full thesis
    Quality20%
    65/ 100

    ROE 12% · Op margin 13%

    Balance sheet15%
    74/ 100

    D/E 0.65 · CR 1.39

    Insider convictionown.
    93/ 100

    3 insiders buying

    Superinvestorown.
    35/ 100

    No tracked superinvestor holds it

    Shareholder yield10%
    75/ 100

    3.05% yield + buyback runway

    Momentum5%
    23/ 100

    3% through 52w range

    Growth5%
    26/ 100

    EPS -20% · Rev 8%

    Risk deduction: 1 pattern flagged · operating leverage appears to have reversed. 2 points removed from composite.

    Designed to surface potentially attractive characteristics — descriptive, not prescriptive. For research and educational purposes only.

    Customise weights
    Drivers
    • • Revenue growth holds near 8%
    • • Operating margin stays around 13%
    • • No major balance-sheet surprises
    Bear
    ~35%
    $32.98
    -17.0% / yr (5y)

    Cyclical earnings prove to be at peak; revenue stalls and the multiple, already low, drifts lower as estimates re-rate down.

    Drivers
    • • Operating margin compresses 200–400 bps
    • • Multiple compresses as estimates roll back
    • • Sentiment de-rates the name to a deeper-value multiple
    Indicative weights
    16.0%
    —
    15.0%

    Editorial dataset · as of 2024-12-31. Sector medians are hand-maintained from public Tadawul / ADX / DFM / QSE / EGX disclosures and indicative Global ex-US references. Live licensed data is on the roadmap. For research and educational purposes only.

    What to watch on the next print
    • • Management explanation of cause — one-off vs structural
    • • Analyst-revision direction over the next 1-2 weeks
  • What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress

    Motley Fool · just now

  • Abbott's Medical Device Strategy Supports Long-Term Growth Outlook

    Zacks · just now

  • Abbott Laboratories: Mispriced Growth Behind Near-Term Noise?

    GuruFocus.com · just now

  • Institutional Own.

    81.4%

    Insider Own.

    0.5%

    Dividend Yield

    3.05%

    Book Value / Share

    $29.89